BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.82
+2.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 381.0K | 699.0K |
| Cost of Revenue | 7.2M | 184.9K | 5.4M | 4.1M | 5.1M |
| Gross Profit | (7.2M) | (184.9K) | (5.4M) | (3.7M) | (4.4M) |
| Operating Expenses | |||||
| R&D Expense | 9.4M | 3.7M | 5.4M | 4.1M | 5.1M |
| SG&A Expense | 8.6M | 4.8M | 3.8M | 4.3M | 4.5M |
| General & Admin Expense | 8.6M | 4.8M | 3.8M | 4.3M | 4.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (7.2M) | (482.5K) | (5.5M) | (4.1M) | (5.1M) |
| Total Operating Expenses | 10.8M | 8.1M | 3.8M | 4.3M | 4.5M |
| Cost and Expenses | 17.9M | 8.3M | 9.2M | 8.4M | 9.6M |
| Operating Income (EBIT) | (17.9M) | (8.3M) | (9.2M) | (8.0M) | (8.9M) |
| Non-Operating | |||||
| Interest Income | 141.7K | 87.0K | 2.0K | 83.0K | 29.0K |
| Interest Expense | 206.9K | 68.5K | — | 41.0K | 53.0K |
| Net Interest Income | (65.2K) | 18.6K | 2.0K | 42.0K | (24.0K) |
| Other Non-Op Income/Expense | 5.5M | 1.9M | 3.2M | 529.0K | 444.0K |
| Non-Operating Income (excl Interest) | (839.0K) | — | (3.4M) | (570.0K) | (497.0K) |
| EBT (Pre-Tax Income) | (12.5M) | (6.3M) | (6.0M) | (7.5M) | (8.5M) |
| Income Tax Expense | (25.4K) | (102.7K) | (250.0K) | (406.0K) | (832.0K) |
| Bottom Line | |||||
| Net Income | (12.1M) | (6.2M) | (5.7M) | (7.1M) | (7.7M) |
| Earnings from Cont. Ops | (12.4M) | (6.2M) | (5.7M) | (7.1M) | (7.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.0M) | (6.2M) | (5.7M) | (7.1M) | (7.7M) |
| Per Share | |||||
| Basic EPS | ($4,891.55) | ($400.00) | ($3,705.65) | ($69,640.00) | ($4,770,680.00) |
| Diluted EPS | ($4,891.55) | ($400.00) | ($3,705.65) | ($69,640.00) | ($4,770,680.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $3,023.81 | $699,000.00 |
| Shares | |||||
| Basic Shares Outstanding | 90327 | 21944 | 1981 | 126 | 1 |
| Diluted Shares Outstanding | 90327 | 21944 | 1981 | 126 | 1 |
| Profitability Metrics | |||||
| EBITDA | (16.8M) | (8.1M) | (9.1M) | (7.2M) | (8.3M) |
| D&A | 304.7K | 184.9K | 117.0K | 283.0K | 174.0K |
| EBIT | (17.1M) | (8.3M) | (9.2M) | (7.4M) | (8.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025